Thiopurines activate an antiviral unfolded protein response that blocks viral glycoprotein accumulation in cell culture infection model
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Enveloped viruses, including influenza A viruses (IAVs) and coronaviruses (CoVs), utilize the host cell secretory pathway to synthesize viral glycoproteins and direct them to sites of assembly. Using an image-based high-content screen, we identified two thiopurines, 6-thioguanine (6-TG) and 6-thioguanosine (6-TGo), that selectively disrupted the processing and accumulation of IAV glycoproteins hemagglutinin (HA) and neuraminidase (NA). Selective disruption of IAV glycoprotein processing and accumulation by 6-TG and 6-TGo correlated with unfolded protein response (UPR) activation and HA accumulation could be partially restored by the chemical chaperone 4-phenylbutyrate (4PBA). Chemical inhibition of the integrated stress response (ISR) restored accumulation of NA monomers in the presence of 6-TG or 6-TGo, but did not restore NA glycosylation or oligomerization. Thiopurines inhibited replication of the human coronavirus OC43 (HCoV-OC43), which also correlated with UPR/ISR activation and diminished accumulation of ORF1ab and nucleocapsid (N) mRNAs and N protein, which suggests broader disruption of coronavirus gene expression in ER-derived cytoplasmic compartments. The chemically similar thiopurine 6-mercaptopurine (6-MP) had little effect on the UPR and did not affect IAV or HCoV-OC43 replication. Consistent with reports on other CoV Spike (S) proteins, ectopic expression of SARS-CoV-2 S protein caused UPR activation. 6-TG treatment inhibited accumulation of full length S0 or furin-cleaved S2 fusion proteins, but spared the S1 ectodomain. DBeQ, which inhibits the p97 AAA-ATPase required for retrotranslocation of ubiquitinated misfolded proteins during ER-associated degradation (ERAD) restored accumulation of S0 and S2 proteins in the presence of 6-TG, suggesting that 6-TG induced UPR accelerates ERAD-mediated turnover of membrane-anchored S0 and S2 glycoproteins. Taken together, these data indicate that 6-TG and 6-TGo are effective host-targeted antivirals that trigger the UPR and disrupt accumulation of viral glycoproteins. Importantly, our data demonstrate for the first time the efficacy of these thiopurines in limiting IAV and HCoV-OC43 replication in cell culture models.
IMPORTANCE
Secreted and transmembrane proteins are synthesized in the endoplasmic reticulum (ER), where they are folded and modified prior to transport. During infection, many viruses burden the ER with the task of creating and processing viral glycoproteins that will ultimately be incorporated into viral envelopes. Some viruses refashion the ER into replication compartments where viral gene expression and genome replication take place. This viral burden on the ER can trigger the cellular unfolded protein response (UPR), which attempts to increase the protein folding and processing capacity of the ER to match the protein load. Much remains to be learned about how viruses co-opt the UPR to ensure efficient synthesis of viral glycoproteins. Here, we show that two FDA-approved thiopurine drugs, 6-TG and 6-TGo, induce the UPR in a manner that impedes viral glycoprotein accumulation for enveloped influenza viruses and coronaviruses. These drugs may impede the replication of viruses that require precise tuning of the UPR to support viral glycoprotein synthesis for the successful completion of a replication cycle.
Article activity feed
-
SciScore for 10.1101/2020.09.30.319863: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Mouse anti-PABP (Santa Cruz, 10E10), Rabbit anti-TIAR (Cell signaling, 8509), 1:3000 rabbit anti-GM130, 1:100 rabit anti-Calnexin, 1:1000 anti-Spike (GeneTex), 1:100 anti-StrepTag (IBA), and 1:800 anti-eIF3A (Cell signaling, 3411), followed by Alexa-coupled donkey or goat secondary antibodies (Thermo Fisher Scientific) at 1:1000 dilution. anti-PABPsuggested: Noneanti-TIAR ( Cell signaling , 8509)suggested: (Cell Signaling Technology Cat# 8509, RRID:AB_10839…SciScore for 10.1101/2020.09.30.319863: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Mouse anti-PABP (Santa Cruz, 10E10), Rabbit anti-TIAR (Cell signaling, 8509), 1:3000 rabbit anti-GM130, 1:100 rabit anti-Calnexin, 1:1000 anti-Spike (GeneTex), 1:100 anti-StrepTag (IBA), and 1:800 anti-eIF3A (Cell signaling, 3411), followed by Alexa-coupled donkey or goat secondary antibodies (Thermo Fisher Scientific) at 1:1000 dilution. anti-PABPsuggested: Noneanti-TIAR ( Cell signaling , 8509)suggested: (Cell Signaling Technology Cat# 8509, RRID:AB_10839263)anti-GM130suggested: (Novus Cat# NB100-2622, RRID:AB_10000741)anti-Calnexinsuggested: Noneanti-Spike ( GeneTex)suggested: Noneanti-StrepTag ( IBA) ,suggested: Noneanti-eIF3Asuggested: (Cell Signaling Technology Cat# 3411, RRID:AB_2096523)Experimental Models: Cell Lines Sentences Resources Cell lines: Human lung adenocarcinoma A549 cells, human embryonic kidney (HEK) 293T and 293A cells, human colorectal adenocarcinoma HCT-8, green monkey kidney (Vero), baby hamster kidney (BHK-21), and Madin-Darby canine kidney (MDCK) cells were all maintained in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific, A549suggested: NoneHEKsuggested: None293Tsuggested: None293Asuggested: NoneMDCKsuggested: CLS Cat# 602280/p823_MDCK_(NBL-2, RRID:CVCL_0422)HCT-8 cells were additionally supplemented with 1X MEM Non-Essential Amino Acids (Gibco) HCT-8suggested: NoneBaby hamster kidney (BHK-21) were maintained in DMEM supplemented with 5% FBS and 100 U/mL penicillin + 100 μg/mL streptomycin + 20 μg/mL-glutamine. BHK-21suggested: NoneIAV-PR8 stocks were generated using the 8-plasmid reverse genetic system, which was provided by Dr. Richard Webby (St. Jude Children’s Research Hospital, Memphis USA); IAV-Udorn was rescued from the 12-plasmid system that was provided by Dr. Yoshi Kawaoka (University of Wisconsin-Madison, Madison, USA); IAV-CA/07 was provided by the Public Health Agency of Canada (PHAC) National Microbiology Laboratory IAV-CA/07suggested: NoneTo generate OC43 stocks, Vero cells were infected at a MOI of 0.05 for 1 h at 33°C in serum-free DMEM. Verosuggested: NoneHEK293T cells were grown on poly-D-lysine coated coverslips and transfected as described above. HEK293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)Software and Algorithms Sentences Resources Statistical analysis: Statistical analysis was performed using PRISM graph pad 8, using a one-way ANOVA multiple comparison test (Tukey) or Two-way ANOVA using the multiple comparison test using Dunnett’s correction. PRISMsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
